Effect of 4 Weeks of Oral Probiotic Desulfovibrio Piger Supplementation on Immunological and Metabolic Parameters in Individuals With Longstanding Type 1 Diabetes

ClinicalTrials.gov ID

NCT07585994

Lead Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER

Overall Status

Recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

20Estimated

Last Update Posted

May 14, 2026Actual

Start Date

May 2026Estimated

Primary Completion Date

May 2028Estimated

Completion Date

May 2028Estimated

Official Title

Effect of 4 Weeks of Oral Probiotic Desulfovibrio Piger Supplementation on Immunological and Metabolic Parameters in Individuals With Longstanding Type 1 Diabetes

Brief Summary

The goal is to establish the effect of oral probiotic Desulfovibrio piger (D. piger) supplementation on immunological and metabolic parameters in individuals with longstanding type 1 diabetes with residual beta cell function. The investigators will perform a double-blind, randomized, placebo-controlled trial in 2x10 participants to measure effects of D. piger on parameters of systemic and intestinal inflammation and residual beta cell function.

Detailed Description

The investigators perform a double-blind, randomized, placebo-controlled trial with two arms (10 participants per arm, total of 20 participants) in adults with longstanding type 1 diabetes with residual beta cell function. The study duration is 6 weeks, with 4 weeks of intervention in which participants will be given D. piger or placebo once daily and 2 weeks of washout period. The main study enpoints include the changes (versus baseline) in parameters of systemic/intestinal inflammation and beta cell function between the placebo and D.piger-treatment arms at the end of treatment (4 weeks). In addition, any long-lasting effects will be determined by assessing the changes in the above described markers after a 2 week washout period (6 weeks).

Secondary endpoints include glucose variability (continuous glucose monitoring, CGM), fecal microbiome composition (including strain engraftment of D. piger, plasma metabolites), immune cell phenotype and frequency and validated questionnaires (gastro-intestinal complaints) at these three timepoints (0,4,6 weeks).

• Type 1 Diabetes Mellitus

• Probiotic dietary supplement
• Placebo

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Males or females, age >18 years
• A diagnosis of type 1 diabetes, with duration of more than 5 years, with minimally one of antiGAD65, IA2, ZnT8 autoantibodies present assessed at diagnosis or routine visits at Diabeter Centrum.
• Evidence of remaining residual beta cell function with detectable UCPCR (more than 0.01 nmol/mmol C-peptide/creatinine ratio) and or fasting plasma C-peptide more than 0.2 mmol/L.
• BMI 18-30 kg/m2

Exclusion Criteria:

• Use of antibiotics or proton-pump inhibitors within the last three months before screening or during study period
• Use of other probiotic supplementation within the last month before screening or during study period
• A history of cholecystectomy
• Overt untreated gastrointestinal disease, inflammatory bowel disease or abnormal bowel habits
• Absence of a large bowel (ie colostomy)
• Evidence for comprised immunity (HIV infection, chemotherapy, other autoimmune diseases, systemic anti-inflammatory therapy)
• History of cardiovascular disaeses (CVD) events
• Hepatic enzymes>2.5 higher than the upper limit of normal range, determined during MARVEL visits/routine visits
• Kidney failure (eGFR <15ml.min/1.73m2), dialysis, kidney transplantation,
• Inability or unwillingness to donate feces or urine.
• Smoking or illicit drug use (e.g. MDMA/amphetamine/cocaine/heroin/GHB) in the past three months or use during the study period.
• Alcohol abuse (equal or above 21 units per week)
• Inability or unwillingness to provide informed consent.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Triple

Lead Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER

m.nieuwdorp@amsterdamumc.nl+31 20-5669111

• Effect of a Probiotic Supplement on Gut Microbiota and Glycemic Control in Patients With Type 1 Diabetes (PRODIAB)

  NCT07062224

  Not yet recruitingInterventionalNot ApplicableUpdated Jul 14, 2025
• Effect of Inulin Supplementation on Glycaemic Control and Immunological Parameters in Type 1 Diabetes (2024)

  NCT07050888

  RecruitingInterventionalNot ApplicableUpdated Jul 3, 2025
• Probiotic Supplementation and Pancreatic β-Cell Function in Type 2 Diabetes

  NCT05765292

  CompletedInterventionalNot ApplicableUpdated Mar 13, 2023
• Effect of Probiotic Supplementation on Fecal Microbiota, Nutritional Status, Metabolic and Inflammatory Parameters in Patients With Type 2 Diabetes Mellitus

  NCT05418179

  Unknown statusInterventionalNot ApplicableUpdated Mar 28, 2023
• The Effect of Single Probiotic on Metabolic Control in Type 2 Diabetes

  NCT05066152

  CompletedInterventionalNot ApplicableUpdated Oct 4, 2021
• The Effect of Probiotics on Type 1 Diabetes Mellitus in Children

  NCT03880760

  CompletedInterventionalNot ApplicableUpdated Aug 4, 2021